Section 4: Clinical Pharmacy Services

4CPS-125

PHARMACEUTICAL CONSULTATIONS DEDICATED TO DIRECT ORAL ANTICOAGULANTS FOR CANCER PATIENTS: A SINGLE-CENTER PROSPECTIVE STUDY

4CPS-124

MONITORING OF HIGH-COST ANTIBIOTIC’S PRESCRIPTIONS IN ORDER TO ENSURE PRESCRIPTIVE APPROPRIATENESS, PATIENT SAFETY AND CONTAINING EXPENDITURE

4CPS-123

SARGRAMOSTIM AND LIPOSOMAL AMPHOTERICIN B FOR THE TREATMENT OF CHRONIC VISCERAL LEISHMANIASIS IN HIV CO-INFECTED PATIENT: A CASE REPORT

4CPS-122

ANALYSIS OF THE USE AND EFFECTIVENESS OF FIDAXOMICIN IN CLOSTRIDIOIDES DIFFICILE INFECTION

4CPS-121

OPTIMISING ANTIDIABETIC TREATMENT FOR ELDERLY PATIENTS ACCORDING TO THEIR FUNCTIONAL STATUS

4CPS-120

EFFICACY OF PEMBROLIZUMAB FOR NON-SMALL CELL LUNG CANCER (NSCLC): PRELIMINARY REAL-WORLD ANALYSIS AND COMPARISON WITH THE PIVOTAL STUDY (PS)

4CPS-119

A REAL-LIFE STUDY OF PHARMACOKINETIC MONITORING: NEPHROTOXIC IMPACT OF AMINOGLYCOSIDES AND VANCOMYCIN

4CPS-118

MEDICATION ADHERENCE TO PSORIASIS TREATMENTS: A POPULATION-BASED STUDY

4CPS-117

UPDATE OF STOPP/START CRITERIA IN 2023: WHAT ARE THE IMPACTS ON OUR PHARMACEUTICAL INTERVENTIONS?

4CPS-116

REAL-WORLD EFFECTIVENESS AND COSTS OF USTEKINUMAB IN PATIENTS DIAGNOSED WITH INFLAMMATORY BOWEL DISEASE

4CPS-115

CHRONIC MIGRAINE REVERSION AND SYMPTOMATIC MEDICATION REDUCTION WITH FREMANEZUMAB

4CPS-114

SUBLINGUAL ADMINISTRATION OF TACROLIMUS IN LIVER TRANSPLANT PATIENT WITH INTESTINAL MALABSORPTION: A CASE REPORT

4CPS-113

THE EFFECTIVENESS OF JANUS KINASE INHIBITORS IN MODERATE TO SEVERE ACTIVE RHEUMATOID ARTHRITIS

4CPS-112

ANTIMICROBIAL STEWARDSHIP PROGRAMME INTERVENTIONS IN INTENSIVE CARE UNIT

4CPS-111

PHARMACEUTICAL INTERVENTIONS IN PATIENTS UNDER CHRONIC OPIOID TREATMENT ADMITTED TO TRAUMATOLOGY UNITS

Pages